JPMorgan raised the firm’s price target on Tenet Healthcare to $140 from $107 and keeps an Overweight rating on the shares. The firm believes diversified managed care organizations and hospitals remain best positioned within its large cap coverage universe. Within managed care, a more defensive approach is still the best way to play the group over the near-term, the analyst tells investors in a research note. JPMorgan remains more cautious on Medicare Advantage given lack of visibility on 2024 cost trends and uncertainty around 2025 bids.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet call volume above normal and directionally bullish
- Tenet Healthcare price target raised to $147 from $113 at Barclays
- Tenet Healthcare price target raised to $130 from $120 at Truist
- Tenet Healthcare price target raised to $136 from $109 at RBC Capital
- Tenet Healthcare price target raised to $122 from $95 at Stephens